- Home
- MEIP vs WETH Comparison
MEIP vs WETH Comparison
Compare MEIP & WETH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- WETH
- Stock Information
- Founded
- MEIP 2000
- WETH 1992
- Country
- MEIP United States
- WETH China
- Employees
- MEIP N/A
- WETH N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- WETH
- Sector
- MEIP Health Care
- WETH
- Exchange
- MEIP Nasdaq
- WETH Nasdaq
- Market Cap
- MEIP 13.3M
- WETH 10.9M
- IPO Year
- MEIP 2003
- WETH N/A
- Fundamental
- Price
- MEIP $2.80
- WETH $0.99
- Analyst Decision
- MEIP Hold
- WETH
- Analyst Count
- MEIP 1
- WETH 0
- Target Price
- MEIP N/A
- WETH N/A
- AVG Volume (30 Days)
- MEIP 13.3K
- WETH 44.3K
- Earning Date
- MEIP 05-13-2025
- WETH 08-18-2025
- Dividend Yield
- MEIP N/A
- WETH N/A
- EPS Growth
- MEIP N/A
- WETH N/A
- EPS
- MEIP N/A
- WETH 0.34
- Revenue
- MEIP N/A
- WETH $41,024,264.00
- Revenue This Year
- MEIP N/A
- WETH N/A
- Revenue Next Year
- MEIP N/A
- WETH N/A
- P/E Ratio
- MEIP N/A
- WETH $2.68
- Revenue Growth
- MEIP 33.76
- WETH 2.86
- 52 Week Low
- MEIP $1.46
- WETH $0.76
- 52 Week High
- MEIP $4.10
- WETH $3.62
- Technical
- Relative Strength Index (RSI)
- MEIP 78.43
- WETH 42.95
- Support Level
- MEIP $2.21
- WETH $0.86
- Resistance Level
- MEIP $2.95
- WETH $0.98
- Average True Range (ATR)
- MEIP 0.15
- WETH 0.06
- MACD
- MEIP 0.05
- WETH -0.00
- Stochastic Oscillator
- MEIP 81.48
- WETH 61.86
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About WETH Wetouch Technology Inc.
Wetouch Technology Inc is a touch panel supplier focused on R & D, production and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots and charging stations. The company sells touchscreen products both domestically in China and internationally, covering the majority of areas in China, Taiwan, South Korea, and Germany.